MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2026

VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL DATA OF TECOTABART VEDOTIN “CLDN18.2 ADC” FOR FIRST-LINE TREATMENT OF GASTRIC CANCER PRESENTED AT 2026 ASCO

VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE I CLINICAL STUDY OF TQB6411 “EGFR/c-Met ADC” PRESENTED AT 2026 ASCO

VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE III CLINICAL STUDY OF BENMELSTOBART IN COMBINATION WITH ANLOTINIB AS FIRST-LINE TREATMENT FOR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER PRESENTED AT 2026 ASCO

VOLUNTARY ANNOUNCEMENT - NALDEMEDINE APPROVED FOR MARKETING

VOLUNTARY ANNOUNCEMENT - DATA FROM TWO PHASE III CLINICAL TRIALS OF BEPIROVIRSEN PRESENTED AT EASL 2026

VOLUNTARY ANNOUNCEMENT - TQB3454 TABLET "IDH1 INHIBITOR" INCLUDED IN THE PRIORITY REVIEW AND APPROVAL PROCEDURES

VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL DATA ON KYLO-0603 PRESENTED AT EASL 2026